Phaseline

Companies › TIXiMED

TIXiMED: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Metabolic and endocrine, Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TIX100
thioredoxin-interacting protein (TXNIP) inhibitor
TXNIPPhase 1Healthy; Health Adult SubjectsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06800729TIX100Phase 1HealthyOtherMay 2025
NCT07675590TIX100Phase 1Health Adult SubjectsMetabolic and endocrineDec 2026

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

TXNIP (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.